Abstract
Abstract Backgrounds: Reactive oxygen species (ROS) is accumulated in cancer cells related to increased metabolism, which is characteristic of cancer progression. With the rapid advance of cancer research, redox regulation has drawn more and more attentions. The superoxide dismutases SOD1 and SOD2 are essential enzymes for eliminating ROS. To date, SOD1 or SOD2 have not been well characterized in non-small cell lung cancer(NSCLC). Here we compared the expression of SOD proteins between normal and cancer tissues and investigated its prognostic significance in NSCLC patients. Method: we detected the expression of SOD1 and SOD2 in 178 NSCLC samples by immunohistochemistry and their clinical significances were analyzed. Western blotting is used to confirm the protein level of SOD1 and SOD2 in the normal and cancer tissues of NSCLC patients. Results: The expression of SOD1 and SOD2 is significantly higher in both adenocarcinoma or squamous cell carcinoma (p<0.0001), compared to matched adjacent normal tissues. Correlation analysis indicates that SOD1 expression is reversely associated with TNM stage, and SOD2 is negatively correlated with tumor size, tumor number and TNM stage remarkably (all p <0.05). Moreover, higher expression of SOD1 and SOD2 is correlated with better prognosis of NSCLC patients. Finally, Univariate and multivariate Cox regression modes further indicate that SOD1 and SOD2 can be used as independent prognostic factors in NSCLC patients. Conclusion: Higher expressions of SOD1 and SOD2 in NSCLC tissues are observed compared to adjacent tissues and indicate better prognosis, suggesting that SOD proteins are potentially useful biomarkers for prognostic evaluation of patients with NSCLC. Key Words: Reactive oxygen species; Non-small cell lung cancer; Superoxide dismutase 1/2; Prognosis. Citation Format: Chen Yin, Ren Wang, Xiao-xing Li, Yang Yang, Mei-yin Zhang, Hui-Yun Wang, Steven X. Zheng. Identification of sod and sod2 as potential prognostic biomarkers for patients with non-small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 5541. doi:10.1158/1538-7445.AM2017-5541
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
